Zachary S. Zumsteg, MD | Cedars-Sinai

Dr. Zachary S. Zumsteg

Claim this profile

Cedars Sinai Medical Center

Studies Oropharyngeal Carcinoma
Studies Oropharyngeal Cancer
10 reported clinical trials
28 drugs studied

Area of expertise

1Oropharyngeal Carcinoma
Zachary S. Zumsteg has run 4 trials for Oropharyngeal Carcinoma. Some of their research focus areas include:
p16 positive
p16 negative
Stage IV
2Oropharyngeal Cancer
Zachary S. Zumsteg has run 3 trials for Oropharyngeal Cancer. Some of their research focus areas include:
p16 positive
p16 negative
high-risk HPV positive

Affiliated Hospitals

Image of trial facility.
Cedars-Sinai Medical Center
Image of trial facility.
Torrance Memorial Medical Center

Clinical Trials Zachary S. Zumsteg is currently running

Image of trial facility.

Chemotherapy + Radiation Therapy

for Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Recruiting1 award Phase 2 & 321 criteria
Image of trial facility.

Cisplatin

for Oropharyngeal Cancer

This is a single institution phase II study that will enroll patients with T0-3N0-2 p16-positive oropharyngeal squamous cell carcinoma (OSCC) undergoing resection of all gross visible disease at the primary site and in the lymph nodes.
Recruiting1 award Phase 27 criteria

More about Zachary S. Zumsteg

Clinical Trial Related12 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Zachary S. Zumsteg has experience with
  • Cisplatin
  • Intensity-Modulated Radiation Therapy
  • Radiation Therapy
  • Degarelix
  • Histrelin
  • Bicalutamide

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Zachary S. Zumsteg specialize in?
Is Zachary S. Zumsteg currently recruiting for clinical trials?
Are there any treatments that Zachary S. Zumsteg has studied deeply?
What is the best way to schedule an appointment with Zachary S. Zumsteg?
What is the office address of Zachary S. Zumsteg?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security